HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary disease.

Abstract
Cysteinyl leukotrienes (LT) are involved in airway inflammation and mucus hypersecretion, characteristically present in asthma and chronic obstructive pulmonary disease (COPD). Zafirlukast is an LT receptor antagonist that improves airway function within 1-3 h after oral administration in subjects with chronic persistent asthma. Through a randomised, double-blind, crossover and placebo-controlled study, we assessed the short-term effects of zafirlukast in patients with severe COPD. We enrolled 23 subjects (seven women) aged 59.4 (1.67) yr [mean (SEM)] with a smoking history of 60.7 (5.2) pack-yr. At screening day the mean FEV(1)was 0.876 (0.72) l; FEV(1) % predicted=35 (3)% and 107 (14) ml increment post-salbutamol. They came two different days, apart from each other at least 72 h. After baseline spirometry, a single oral dose of 40 mg zafirlukast or the corresponding placebo was administered. FVC and FEV(1) was measured every 30 min until 2 hrs. On zafirlukast day, the mean FEV(1) at 90 min [0.813 (0.64) l] and the mean FVC at 90 min [1.76 (0.1) l] were significantly higher than the respective means at placebo day (mean FEV(1)=0.747 (0.55) l; mean FVC=1.63 (0.1) l; p<0.05 Tukey Kramer multiple comparisons test). The maximum mean increase in FEV(1) was 75 (19) ml. A positive correlation was found between absolute response to salbutamol in FEV(1) and the response to zafirlukast (r=0.41; p<0.04). In conclusion, these findings suggest that zafirlukast has a bronchodilator or antibronchoconstrictor effect in COPD patients with severe airflow limitation.
AuthorsLuis J Nannini Jr, Daniela M Flores
JournalPulmonary pharmacology & therapeutics (Pulm Pharmacol Ther) Vol. 16 Issue 5 Pg. 307-11 ( 2003) ISSN: 1094-5539 [Print] England
PMID12877822 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Bronchodilator Agents
  • Indoles
  • Phenylcarbamates
  • Sulfonamides
  • Tosyl Compounds
  • Albuterol
  • zafirlukast
Topics
  • Administration, Oral
  • Aged
  • Albuterol (therapeutic use)
  • Bronchodilator Agents (therapeutic use)
  • Female
  • Humans
  • Indoles
  • Lung (physiopathology)
  • Male
  • Middle Aged
  • Phenylcarbamates
  • Pulmonary Disease, Chronic Obstructive (drug therapy)
  • Sulfonamides
  • Tosyl Compounds (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: